BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
GROW
U.S. Global Investors, Inc.
There isn't enough reported data to score GROW yet.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
GROW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| N/A | |
| N/A |
GROW's revenue is currently healthy, and its profitability is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like GROW.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over GROW in the historical PE scenario, which offers more potential upside but is not a forecast.
GROW PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 4x | $0.52 | -79% |
| Fair | 13x | $1.68 | -33% |
| Current | 19x | $2.52 | — |
| Expensive | 35x | $4.53 | +80% |
Historical ranges are pointers, not guarantees.
GROW's PE is 19x, but its earnings don't support one, so it isn't a reliable read right now.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
GROW Forward outlook
There aren't enough analyst estimates for GROW to show an outlook.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over GROW on earnings, with more consistent year-over-year improvement.
GROW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.13 | +86% |
| Q2 2026 | $0.24 | +$0.27 |
| Q1 2026 | $0.25 | +$0.26 |
| Q4 2025 | $0.01 | -50% |
| Q3 2025 | $0.07 | -42% |
| Q2 2025 | -$0.03 | -133% |
| Q1 2025 | -$0.01 | -108% |
| Q4 2024 | $0.02 | -91% |
GROW's earnings per share have fallen from their peak: $0.13 over the past year, against $2.15 in late 2021.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over GROW on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over GROW on profitability, with a higher operating margin.
GROW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.7M | +18% |
| Q2 2026 | $2.7M | +39% |
| Q1 2026 | $2.8M | +31% |
| Q4 2025 | $2.5M | +13% |
| Q3 2025 | $2.3M | +4.4% |
| Q2 2025 | $2M | -20% |
| Q1 2025 | $2.1M | -19% |
| Q4 2024 | $2.2M | -21% |
GROW's revenue is recovering but still below its 2021 peak: $3M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.1% | +25 points |
| Q2 2026 | -3.2% | +48 points |
| Q1 2026 | 3.2% | +46 points |
| Q4 2025 | -3.5% | +21 points |
| Q3 2025 | -23% | +3 points |
| Q2 2025 | -51% | -35 points |
| Q1 2025 | -42% | -24 points |
| Q4 2024 | -24% | -31 points |
GROW's operating margin was 2.1% last quarter, up 25 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the stronger cash trend. Its trailing FCF is up 119% versus its history, compared with GROW at down 72%.
GROW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $483K | +$515K |
| Q2 2026 | $203K | +$218K |
| Q1 2026 | $275K | +$699K |
| Q3 2025 | -$32K | -300% |
| Q2 2025 | -$15K | -115% |
| Q1 2025 | -$424K | -$299K |
| Q4 2024 | -$406K | -$380K |
| Q3 2024 | $16K | -98% |
GROW's free cash flow was $929,000 over the past year, against −$829,000 the year before. Free cash flow isn't a meaningful measure for financial services companies like GROW.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over GROW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
GROW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.8% | -360K shares |
| 1 year | -5% | -648K shares |
| 3 years | -15% | -2.1M shares |
| 5 years | -18% | -2.7M shares |
| Available history | -19% | -2.8M shares |
GROW has 12M diluted shares, down 5% from a year ago, with $2M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $320,000 |
| Q2 2026 | $364,000 |
| Q1 2026 | $552,000 |
| Q4 2025 | $666,000 |
| Q3 2025 | $390,000 |
| Q2 2025 | $395,000 |
| Q1 2025 | $453,000 |
| Q4 2024 | $591,000 |
GROW spent $2M buying back its own shares over the past year, up 4% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
GROW Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2,691.6x | Net Cash |
| Q1 2024 | -61.7x | Net Cash |
| Q4 2023 | -16.3x | Net Cash |
| Q3 2023 | -11.2x | Net Cash |
| Q2 2023 | -6.7x | Net Cash |
| Q1 2023 | -4.0x | Net Cash |
| Q4 2022 | -2.9x | Net Cash |
| Q3 2022 | -2.3x | Net Cash |
GROW has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
GROW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.3 | Neutral |
| Stochastic | 6.4 | Oversold |
GROW's weekly RSI is 38 (neutral) and its Stochastic is 6 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over GROW on valuation relative to its sector.
GROW PE vs Financial Services Sector
| Metric | GROW | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 13x | 49% above |
| PE % | 60 | 63 | 3 pts below |
GROW is trading at 19x earnings, a 49% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has the edge over GROW on trend strength, trading above more of its moving averages.
GROW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.72 | 7.4% below |
| 20 week MA | $2.92 | 14% below |
| 50 week MA | $2.84 | 11% below |
| 100 week MA | $2.62 | 3.8% below |
| 200 week MA | $2.68 | 6% below |
GROW is in a downtrend: it's below all five of its weekly moving averages, and 6% below its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
GROW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.33 | $4.62 | +247% |
| 2021 | $4.62 | $4.55 | -1.5% |
| 2022 | $4.55 | $2.65 | -42% |
| 2023 | $2.65 | $2.82 | +6.4% |
| 2024 | $2.82 | $2.45 | -13% |
| 2025 | $2.45 | $2.47 | +0.8% |
| 2026 YTD | $2.47 | $2.52 | +2% |
GROW has the edge over BAC on returns for 2026, with the stronger performance.